Limbal Stem Cell Deficiency (LSCD) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Limbal Stem Cell Deficiency (LSCD) – Drugs In Development, 2024 report and make more profitable business decisions.
Limbal Stem Cell Deficiency (LSCD) is characterized by a loss or deficiency of the stem cells in the limbus that are important for the regeneration of corneal epithelium and to the barrier function of the limbus. Due the loss of stem cells, the corneal epithelium is unable to repair and renew itself, resulting in in epithelial breakdown and persistent epithelial defects, corneal conjunctivalization and neovascularization, corneal scarring, and chronic inflammation. All of these contribute to loss of corneal clarity, potential vision loss, chronic pain, photophobia, and failure of keratoplasty if done before addressing this. LSCD has been associated with PAX6 gene mutations. Other causes include inflammatory conditions such as those seen in Steven-Johnsons syndrome (SJS), ocular cicatricial pemphigoid, graft versus host disease, infections, and trauma. LSCD can be diagnosed using corneal impression cytology along with clinical signs and symptoms. It can be reversed if treated early. The treatment options include corneal transplant, limbal graft, scleral lenses, autologous serum eye drops, stem cell therapies, discontinuation of soft contact lens wear, and preservative-free lubrication.
The Limbal Stem Cell Deficiency (LSCD) drugs in development market research report provide comprehensive information on the therapeutics under development for Limbal Stem Cell Deficiency (LSCD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Limbal Stem Cell Deficiency (LSCD) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Limbal Stem Cell Deficiency (LSCD) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 5 molecules, with 5 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Limbal Stem Cell Deficiency (LSCD) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Limbal Stem Cell Deficiency (LSCD) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Limbal Stem Cell Deficiency (LSCD) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Limbal Stem Cell Deficiency (LSCD) reports